In 2026, the impact of cannabis rescheduling is expected to be far more visible in marijuana stock performance. Much more than in the initial announcement of cannabis becoming a Class 3 substance. While 2025 seemed to be a transition year, 2026 could mark another pivot point. Specifically, one where improved business operations begin to consistently translate into stronger equity valuations across the sector. Investor sentiment may also shift meaningfully.
As On The Money has been reporting since April, our famously drug-and-drink-averse president has been inching ever closer to making marijuana significantly less criminal in the eyes of the federal government.
Trulieve Founder, Chair, and CEO Kim Rivers joins 'Fast Money' with reaction to Pres. Trump reclassifying marijuana.
President Donald Trump on Thursday signed an executive order directing the federal government to move marijuana from Schedule I to Schedule III, potentially easing regulatory and financial constraints for cannabis companies while keeping recreational use illegal under federal law. The order instructs the attorney general to expedite the ongoing process of rescheduling marijuana, which is currently classified alongside heroin and LSD as a Schedule I drug — considered to have a high potential for abuse and no accepted medical use.
Cannabis stocks jumped Friday as the White House moved to significantly ease federal restrictions on marijuana. Brandon Gomez has the latest on the timing of a potential Executive Order and why the industry says it's “more optimistic” this time around.
With 2026 showing to be a big year for reform, how will this impact marijuana stocks? Looking back over the years, it is clear that marijuana stocks have seen their best trading when positive news on reform is released. The speculation of what could happen drives the market action up often. If investors feel the reform is important enough, you'll then see some increased buying action.
The big question for marijuana stock investors is how the market will react to the newly passed bill to reverse the 2018 Farm Bill. A new bill was recently passed with language that essentially overturned the Hemp laws in the USA. Many legal operators produced hemp and CBD products to ensure compliance under the bill as a way to energetically take part in the industry. Now, legal operators in legal states cultivating cannabis vs hemp have an entirely different legal road map to follow. Yet this is what many are calling a step backwards, and rightfully so.
Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.04 per share a year ago.
Cannabis stocks could rally on hopes for new hemp regulations and Trump's possible softer stance on marijuana, fueling investor optimism across the industry.
Key Points in This Article: Cannabis stocks surged in 2018-2019 on federal legalization hopes but crashed as progress stalled.
Marijuana stocks have begun to gain traction in trading, exhibiting moderate consistency. But why did this occur, and what is happening to bring such momentum to the sector? Once again, the backing and favorable side of passing federal reform for cannabis is being discussed by top politicians. In recent talks, President Donald Trump voiced his stance on cannabis and how it should be legalized under the right conditions.
Aurora Cannabis stock slips after Q1 earnings miss, but revenue climbs 17.5% year over year on strong global medical cannabis demand.